胃癌是全球第五大常见癌症和第四大癌症死亡原因。研究表明,曲妥珠单抗联合标准化疗可显著提高HER-2阳性晚期疾病的总体生存率。近年来,随着影像技术的发展和广泛应用,影像技术和影像手段应用于临床基因检测成为一大趋势,本文对预测HER-2状态的相关影像学研究现状及进展作一综述。
Gastric cancer is the fifth common cancer and the fourth leading cause of cancer death worldwide. Studies have shown that trastuzumab combined with standard chemotherapy can significantly im-prove the overall survival rate of HER-2 positive advanced diseases. In recent years, with the de-velopment and wide application of imaging technology, the application of imaging technology and imaging methods in clinical gene detection has become a major trend. This paper reviews the cur-rent status and progress of imaging research on predicting HER-2 status.
胃癌,HER-2,CT,MRI,PER/CT,影像组学, Gastric Cancer HER-2 CT MRI PER/CT Radiomics摘要
Imaging Progress of Human Epidermal Growth Factor Receptor 2 in Gastric Cancer
Shuchang Zhang1, Shengbao Wen2*
1Graduate School of Qinghai University, Xining Qinghai
2Affiliated Hospital of Qinghai University, Xining Qinghai
Received: May 10th, 2022; accepted: May 27th, 2022; published: Jun. 13th, 2022
ABSTRACT
Gastric cancer is the fifth common cancer and the fourth leading cause of cancer death worldwide. Studies have shown that trastuzumab combined with standard chemotherapy can significantly improve the overall survival rate of HER-2 positive advanced diseases. In recent years, with the development and wide application of imaging technology, the application of imaging technology and imaging methods in clinical gene detection has become a major trend. This paper reviews the current status and progress of imaging research on predicting HER-2 status.
张舒畅,温生宝. 胃癌人表皮生长因子受体2影像学进展Imaging Progress of Human Epidermal Growth Factor Receptor 2 in Gastric Cancer[J]. 临床医学进展, 2022, 12(06): 5136-5141. https://doi.org/10.12677/ACM.2022.126744
参考文献ReferencesSung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
<br>https://doi.org/10.3322/caac.21660Tanner, M., Hollmen, M., Junttila, T.T., et al. (2005) Amplification of HER-2 in Gastric Carcinoma: Association with Topoisomerase IIalpha Gene Amplification, Intestinal Type, Poor Prog-nosis and Sensitivity to Trastuzumab. Annals of Oncology, 16, 273-278. <br>https://doi.org/10.1093/annonc/mdi064Hudis, C.A. (2007) Trastuzumab—Mechanism of Action and Use in Clinical Practice. The New England Journal of Medicine, 357, 39-51. <br>https://doi.org/10.1056/NEJMra043186Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Ad-vanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
<br>https://doi.org/10.1016/S0140-6736(10)61121-XJoshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. <br>https://doi.org/10.3322/caac.21657Abrahao-Machado, L.F. and Scapulatempo-Neto, C. (2016) HER2 Testing in Gastric Cancer: An Update. World Journal of Gastroenterology, 22, 4619-4625. <br>https://doi.org/10.3748/wjg.v22.i19.4619中国抗癌协会胃癌专业委员会. 胃癌诊治难点中国专家共识(2020版) [J]. 中国实用外科杂志, 2020, 40(8): 869-904.Kim, S.H., Kim, S.H., Kim, M.A., et al. (2015) CT Differentiation of Poorly-Differentiated Gastric Neuroendocrine Tumours from Well-Differentiated Neuroendocrine Tu-mours and Gastric Adenocarcinomas. European Radiology, 25, 1946-1957. <br>https://doi.org/10.1007/s00330-015-3600-zAhadi, M., Moradi, A., Musavinejad, L., et al. (2020) The Ex-pression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological In-dicators: A Retrospective Study. Asian Pacific Journal of Cancer Prevention, 21, 1607-1614. <br>https://doi.org/10.31557/APJCP.2020.21.6.1607Wang, N., Wang, X., Li, W., et al. (2020) Con-trast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? Cancer Management and Research, 12, 1211-1219. <br>https://doi.org/10.2147/CMAR.S230138李玉珠, 李亚平, 李彦良. HER-2蛋白表达与多层螺旋CT胃癌征象相关性分析及应用[J]. 影像科学与光化学, 2021, 39(5): 684-688.赵瑾, 陈海燕, 丁信法, 等. 胃癌MSCT表现和临床病理特征与HER2表达的相关性研究[J]. 实用肿瘤杂志, 2020, 35(3): 201-207.潘圣宝, 雷振. 进展期胃癌多层螺旋CT表现与HER2表达的相关性[J]. 中国医学影像学杂志, 2019, 27(4): 282-285.刘洋, 高剑波, 岳松伟, 等. CT强化率、灌注参数与胃癌病灶中HER2表达的关系[J]. 世界华人消化杂志, 2015, 23(3): 426-431.Lee, J.S., Kim, S.H., Im, S.A., et al. (2017) Human Epidermal Growth Factor Receptor 2 Expres-sion in Unresectable Gastric Cancers: Relationship with CT Characteristics. Korean Journal of Radiology, 18, 809-820.
<br>https://doi.org/10.3348/kjr.2017.18.5.809郑红伟, 彭晓博, 郑凌云, 等. 胃癌CT征象与HER2基因表达的相关性研究[J]. 中国CT和MRI杂志, 2021, 19(1): 161-164.Petralia, G., Preda, L., D’andrea, G., et al. (2010) CT Perfusion in Solid-Body Tumours. Part I: Technical Issues. La Radiologia Medica, 115, 843-857. <br>https://doi.org/10.1007/s11547-010-0519-y黄列彬, 龙晚生, 陈钦贤, 等. CT灌注成像对进展期胃癌HER2表达状态的评估价值[J]. 遵义医科大学学报, 2020, 43(5): 641-645.李慧, 征锦, 叶靖. 低剂量CT灌注成像对胃癌分化程度评估及Her2、EGFR水平相关性研究[J]. 中华消化病与影像杂志(电子版), 2020, 10(6): 252-255.张笑, 黄伟, 宋彬. 基于CT平扫图像的纹理分析区分胃癌HER2表达的可行性研究[J]. 中国普外基础与临床杂志, 2021, 28(9): 1221-1226.Wang, Y., Yu, Y., Han, W., et al. (2021) CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Academic Radiology, 28, e86-e92. <br>https://doi.org/10.1016/j.acra.2020.02.018Zhao, H., Li, W., Huang, W., et al. (2021) Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients with Gastric Cancer. AJR. American Journal of Roentgenology, 216, 1539-1548. <br>https://doi.org/10.2214/AJR.20.23528Wang, S., Chen, Y., Zhang, H., et al. (2021) The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram. Frontiers in Oncology, 11, Article ID: 707686. <br>https://doi.org/10.3389/fonc.2021.707686He, J., Shi, H., Zhou, Z., et al. (2015) Correlation between Appar-ent Diffusion Coefficients and HER2 Status in Gastric Cancers: Pilot Study. BMC Cancer, 15, Article No. 749. <br>https://doi.org/10.1186/s12885-015-1726-7Ji, C., Zhang, Q., Guan, W., et al. (2017) Role of Intravoxel In-coherent Motion MR Imaging in Preoperative Assessing HER2 Status of Gastric Cancers. Oncotarget, 8, 49293-49302. <br>https://doi.org/10.18632/oncotarget.17570王铮, 苏丹柯, 赖少侣, 等. 胃癌MRI非形态学表征与Her-2表达水平的相关性分析[J]. 临床放射学杂志, 2019, 38(2): 281-285.王姣, 次旦旺久, 卢海燕, 等. 胃癌DWI ADC值与HER-2、CEA表达的相关性分析[J]. 现代肿瘤医学, 2020, 28(21): 3749-3752.张霄, 曲金荣, 张宏凯, 等. 动态对比增强MRI定量参数直方图分析在胃癌HER2表达中的应用价值[J]. 放射学实践, 2021, 36(9): 1110-1115.Erturk, S.A., Hasbek, Z. and Ozer, H. (2021) The Relationship between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy, 30, 150-157.
<br>https://doi.org/10.4274/mirt.galenos.2021.78055Celli, R., Colunga, M., Patel, N., et al. (2016) Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. Journal of Nuclear Medicine Technology, 44, 234-238.
<br>https://doi.org/10.2967/jnmt.116.181479弭丽丽, 殷飞, 雷连会, 等. 18F-FDG PET/CT相关参数与胃癌患者HER2表达状态的相关性研究[J]. 中国肿瘤临床, 2021, 48(6): 301-305.Chen, R., Zhou, X., Liu, J., et al. (2016) Relationship between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. The Journal of Nu-clear Medicine, 57, 1040-1044. <br>https://doi.org/10.2967/jnumed.115.171165Park, J.S., Lee, N., Beom, S.H., et al. (2018) The Prognostic Value of Volume-Based Parameters Using 18F-FDG PET/CT in Gastric Cancer According to HER2 Status. Gastric Cancer, 21, 213-224.
<br>https://doi.org/10.1007/s10120-017-0739-0Bai, L., Guo, C.H., Zhao, Y., et al. (2017) SUVmax of 18F-FDG PET/CT Correlates to Expression of Major Chemotherapy-Related Tumor Markers and Serum Tumor Markers in Gastric Adenocarcinoma Patients. Oncology Reports, 37, 3433-3440. <br>https://doi.org/10.3892/or.2017.5631